Diligence memo · auto-generated · as of July 2, 2026

Accolade, Inc.

Accolade, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Accolade, Inc. operates in Other Health Care, based in PLYMOUTH MEETING. Contact Accolade today to see what Personalized Healthcare is all about.

Capital & rounds (filed)filed

Accolade, Inc. has raised $661M in disclosed capital across 11 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).

Largest single filing: $325M on 2021-06-09.

Most recent recorded round closed around 2021-09-30.

Valuation (modeled)modeled

Provath models Accolade, Inc. at approximately $200M (range $60M–$380M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.06× the median modeled value of Series D+ Other Health Care companies in 2019–2021 (26 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 4.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 28.9× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 100% of Other Health Care peers (5377 compared).

Modeled value ranks above 87% of those peers.

Closest niche peers: ZAHN Parent, LLC, Covetrus, Inc., EQH Parent, LLC, SonerMed, LLC, Fs Usme Lp.

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.